Main clinicohematologic characteristics at diagnosis in 261 patients with PV treated with HU
| Clinicohematologic characteristic . | Value . |
|---|---|
| Age, y* | 64 (16-88) |
| Sex, male/female | 118/143 |
| Cardiovascular risk factors, no. (%)† | 183 (71) |
| PV-related symptoms, no. (%)‡ | 111 (43) |
| Thrombosis prior to HU start, no. (%) | 90 (34.5) |
| Palpable splenomegaly, no. (%) | 64/257 (24.5) |
| Radiologic splenomegaly, no. (%) | 96/187 (51) |
| Hemoglobin, g/L* | 178 (120-238) |
| Leukocytes, × 109/L* | 10.7 (4.2-29.0) |
| > 10 × 109/L, no. (%) | 147 (56) |
| Platelets, × 109/L* | 520 (155-1481) |
| > 500 × 109/L, no. (%) | 136 (52) |
| JAK2 mutation, no. (%) | 214/225 (95) |
| V617F, no. (%) | 209/214 (98) |
| Exon 12, no. (%) | 5/214 (2) |
| Clinicohematologic characteristic . | Value . |
|---|---|
| Age, y* | 64 (16-88) |
| Sex, male/female | 118/143 |
| Cardiovascular risk factors, no. (%)† | 183 (71) |
| PV-related symptoms, no. (%)‡ | 111 (43) |
| Thrombosis prior to HU start, no. (%) | 90 (34.5) |
| Palpable splenomegaly, no. (%) | 64/257 (24.5) |
| Radiologic splenomegaly, no. (%) | 96/187 (51) |
| Hemoglobin, g/L* | 178 (120-238) |
| Leukocytes, × 109/L* | 10.7 (4.2-29.0) |
| > 10 × 109/L, no. (%) | 147 (56) |
| Platelets, × 109/L* | 520 (155-1481) |
| > 500 × 109/L, no. (%) | 136 (52) |
| JAK2 mutation, no. (%) | 214/225 (95) |
| V617F, no. (%) | 209/214 (98) |
| Exon 12, no. (%) | 5/214 (2) |